{
    "references": [
        {
            "bibentry": "Brown, NC, Reichard, P. Role of effector binding in allosteric control of ribonucleoside diphosphate reductase. J Mol Biol 1969; 46: 39–55. PMID: 4902212",
            "process_entry": "True",
            "doi": "10.1016/0022-2836(69)90056-4",
            "pmid": "4902212",
            "xmlid": "CIT0001"
        },
        {
            "bibentry": "Stubbe, J, Ge, J, Yee, CS. The evolution of ribonucleotide reduction revisited. Trends Biochem Sci 2001; 26: 93–9. PMID: 11166566",
            "process_entry": "True",
            "doi": "10.1016/s0968-0004(00)01764-3",
            "pmid": "11166566",
            "xmlid": "CIT0002"
        },
        {
            "bibentry": "Jordan, A, Reichard, P. Ribonucleotide reductases. Annu Rev Biochem 1998; 67: 71–98. PMID: 9759483",
            "process_entry": "True",
            "doi": "10.1146/annurev.biochem.67.1.71",
            "pmid": "9759483",
            "xmlid": "CIT0003"
        },
        {
            "bibentry": "Kolberg, M, Strand, KR, Graff, P, Andersson, KK. Structure, function, and mechanism of ribonucleotide reductases. Biochim Biophys Acta 2004; 1699: 1–34. PMID: 15158709",
            "process_entry": "True",
            "doi": "10.1016/j.bbapap.2004.02.007",
            "pmid": "15158709",
            "xmlid": "CIT0004"
        },
        {
            "bibentry": "Weinberg, G, Ullman, B, Martin, DW, Jr.. Mutator phenotypes in mammalian cell mutants with distinct biochemical defects and abnormal deoxyribonucleoside triphosphate pools. Proc Natl Acad Sci USA 1981; 78: 2447–51. PMID: 7017732",
            "process_entry": "True",
            "doi": "10.1073/pnas.78.4.2447",
            "pmid": "7017732",
            "pmcid": "PMC319363",
            "xmlid": "CIT0005"
        },
        {
            "bibentry": "Kunz, BA, Kohalmi, SE, Kunkel, TA, et al. International Commission for Protection Against Environmental Mutagens and Carcinogens. Deoxyribonucleoside triphosphate levels: a critical factor in the maintenance of genetic stability. Mutat Res 1994; 318: 1–64. PMID: 7519315",
            "process_entry": "True",
            "doi": "10.1016/0165-1110(94)90006-x",
            "pmid": "7519315",
            "xmlid": "CIT0006"
        },
        {
            "bibentry": "Huang, M, Zhou, Z, Elledge, SJ. The DNA replication and damage checkpoint pathways induce transcription by inhibition of the Crt1 repressor. Cell 1998; 94: 595–605. PMID: 9741624",
            "process_entry": "True",
            "doi": "10.1016/s0092-8674(00)81601-3",
            "pmid": "9741624",
            "xmlid": "CIT0007"
        },
        {
            "bibentry": "Yao, R, Zhang, Z, An, X, et al. Subcellular localization of yeast ribonucleotide reductase regulated by the DNA replication and damage checkpoint pathways. Proc Natl Acad Sci USA 2003; 100: 6628–33. PMID: 12732713",
            "process_entry": "True",
            "doi": "10.1073/pnas.1131932100",
            "pmid": "12732713",
            "pmcid": "PMC164498",
            "xmlid": "CIT0008"
        },
        {
            "bibentry": "Zhao, X, Muller, EG, Rothstein, R. A suppressor of two essential checkpoint genes identifies a novel protein that negatively affects dNTP pools. Mol Cell 1998; 2: 329–40. PMID: 9774971",
            "process_entry": "True",
            "doi": "10.1016/s1097-2765(00)80277-4",
            "pmid": "9774971",
            "xmlid": "CIT0009"
        },
        {
            "bibentry": "Brown, NC, Canellakis, ZN, Lundin, B, et al. Ribonucleoside diphosphate reductase. Purification of the two subunits, proteins B1 and B2. Eur J Biochem 1969; 9: 561–73. PMID: 4896737",
            "process_entry": "True",
            "doi": "10.1111/j.1432-1033.1969.tb00646.x",
            "pmid": "4896737",
            "xmlid": "CIT0010"
        },
        {
            "bibentry": "Holmgren, A, Reichard, P, Thelander, L. Enzymatic synthesis of deoxyribonucleotides, 8. The effects of ATP and dATP in the CDP reductase system from E. coli. Proc Natl Acad Sci USA 1965; 54: 830–6. PMID: 5324398",
            "process_entry": "True",
            "doi": "10.1073/pnas.54.3.830",
            "pmid": "5324398",
            "pmcid": "PMC219751",
            "xmlid": "CIT0011"
        },
        {
            "bibentry": "Jordheim, LP, Guittet, O, Lepoivre, M, et al. Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol Cancer Ther 2005; 4: 1268–76. PMID: 16093443",
            "process_entry": "True",
            "doi": "10.1158/1535-7163.mct-05-0121",
            "pmid": "16093443",
            "xmlid": "CIT0012"
        },
        {
            "bibentry": "Jordheim, LP, Seve, P, Tredan, O, Dumontet, C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol 2011; 12: 693–702. PMID: 21163702",
            "process_entry": "True",
            "doi": "10.1016/s1470-2045(10)70244-8",
            "pmid": "21163702",
            "xmlid": "CIT0013"
        },
        {
            "bibentry": "Shao, J, Zhou, B, Chu, B, Yen, Y. Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 2006; 6: 409–31. PMID: 16918309",
            "process_entry": "True",
            "doi": "10.2174/156800906777723949",
            "pmid": "16918309",
            "xmlid": "CIT0014"
        },
        {
            "bibentry": "Stearns, B, Losee, KA, Bernstein, J. Hydroxyurea. A new type of potential antitumour agent. J Med Chem 1963; 6: 201. PMID: 14188794",
            "process_entry": "True",
            "doi": "10.1021/jm00338a026",
            "pmid": "14188794",
            "xmlid": "CIT0015"
        },
        {
            "bibentry": "Donehower, RC. An overview of the clinical experience with hydroxyurea. Semin Oncol 1992; 19: 11–9.",
            "process_entry": "True",
            "xmlid": "CIT0016"
        },
        {
            "bibentry": "Huang, P, Chubb, S, Plunkett, W. Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem 1990; 265: 16617–25. PMID: 1697861",
            "process_entry": "True",
            "pmid": "1697861",
            "xmlid": "CIT0017"
        },
        {
            "bibentry": "Heinemann, V, Xu, YZ, Chubb, S, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. Mol Pharmacol 1990; 38: 567–72. PMID: 2233693",
            "process_entry": "True",
            "pmid": "2233693",
            "xmlid": "CIT0018"
        },
        {
            "bibentry": "Parker, WB, Shaddix, SC, Chang, CH, et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. Cancer Res 1991; 51: 2386–94. PMID: 1707752",
            "process_entry": "True",
            "pmid": "1707752",
            "xmlid": "CIT0019"
        },
        {
            "bibentry": "Parker, WB, Shaddix, SC, Rose, LM, et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-beta-D-ribofuranosyl)adenine in CEM cells. Mol Pharmacol 1999; 55: 515–20. PMID: 10051535",
            "process_entry": "True",
            "pmid": "10051535",
            "xmlid": "CIT0020"
        },
        {
            "bibentry": "Griffig, J, Koob, R, Blakley, RL. Mechanisms of inhibition of DNA Synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res 1989; 49: 6923–8. PMID: 2573423",
            "process_entry": "True",
            "pmid": "2573423",
            "xmlid": "CIT0021"
        },
        {
            "bibentry": "Avery, TL, Rehg, JE, Lumm, WC, et al. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Res 1989; 49: 4972–8. PMID: 2569929",
            "process_entry": "True",
            "pmid": "2569929",
            "xmlid": "CIT0022"
        },
        {
            "bibentry": "Xie, C, Plunkett, W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 1995; 55: 2847–52. PMID: 7540950",
            "process_entry": "True",
            "pmid": "7540950",
            "xmlid": "CIT0023"
        },
        {
            "bibentry": "King, RS. Gemcitabine. New first-line therapy for pancreatic cancer. Cancer Pract 1996; 4: 353–4. PMID: 9128490",
            "process_entry": "True",
            "pmid": "9128490",
            "xmlid": "CIT0024"
        },
        {
            "bibentry": "Baker, CH, Banzon, J, Bollinger, JM, et al. 2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 1991; 34: 1879–84. PMID: 2061926",
            "process_entry": "True",
            "doi": "10.1021/jm00110a019",
            "pmid": "2061926",
            "xmlid": "CIT0025"
        },
        {
            "bibentry": "Gandhi, V, Plunkett, W. Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 1990; 50: 3675–80. PMID: 2340517",
            "process_entry": "True",
            "pmid": "2340517",
            "xmlid": "CIT0026"
        },
        {
            "bibentry": "Wang, J, Lohman, GJ, Stubbe, J. Enhanced subunit interactions with gemcitabine-5'-diphosphate inhibit ribonucleotide reductases. Proc Natl Acad Sci USA 2007; 104: 14324–9. PMID: 17726094",
            "process_entry": "True",
            "doi": "10.1073/pnas.0706803104",
            "pmid": "17726094",
            "pmcid": "PMC1964847",
            "xmlid": "CIT0027"
        },
        {
            "bibentry": "Heinemann, V, Schulz, L, Issels, RD, Plunkett, W. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol 1995; 22: 11–8.",
            "process_entry": "True",
            "xmlid": "CIT0028"
        },
        {
            "bibentry": "Heinemann, V, Xu, YZ, Chubb, S, et al. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. Cancer Res 1992; 52: 533–9. PMID: 1732039",
            "process_entry": "True",
            "pmid": "1732039",
            "xmlid": "CIT0029"
        },
        {
            "bibentry": "Honeywell, RJ, Ruiz van Haperen, VW, Veerman, G, et al. Inhibition of thymidylate synthase by 2',2'-difluoro-2'-deoxycytidine (Gemcitabine) and its metabolite 2',2'-difluoro-2'-deoxyuridine. Int J Biochem Cell Biol 2015; 60: 73–81. PMID: 25562513",
            "process_entry": "True",
            "doi": "10.1016/j.biocel.2014.12.010",
            "pmid": "25562513",
            "xmlid": "CIT0030"
        },
        {
            "bibentry": "Heinemann, V. Ongoing selective internal radiation therapy-based studies in the treatment of liver-dominant metastatic colorectal cancer. Future Oncol (London, England) 2014; 10: 37–9.",
            "process_entry": "True",
            "xmlid": "CIT0031"
        },
        {
            "bibentry": "Heinemann, V, Plunkett, W. Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine. Biochem Pharmacol 1989; 38: 4115–21. PMID: 2688654",
            "process_entry": "True",
            "doi": "10.1016/0006-2952(89)90693-x",
            "pmid": "2688654",
            "xmlid": "CIT0032"
        },
        {
            "bibentry": "Pourquier, P, Gioffre, C, Kohlhagen, G, et al. Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I. Clin Cancer Res 2002; 8: 2499–504. PMID: 12171875",
            "process_entry": "True",
            "pmid": "12171875",
            "xmlid": "CIT0033"
        },
        {
            "bibentry": "Pourquier, P, Pilon, AA, Kohlhagen, G, et al. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. J Biol Chem 1997; 272: 26441–7. PMID: 9334220",
            "process_entry": "True",
            "doi": "10.1074/jbc.272.42.26441",
            "pmid": "9334220",
            "xmlid": "CIT0034"
        },
        {
            "bibentry": "Ahmad, MF, Alam, I, Huff, SE, et al. Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule. Proc Natl Acad Sci USA 2017; 114: 8241–6. PMID: 28716944",
            "process_entry": "True",
            "doi": "10.1073/pnas.1620220114",
            "pmid": "28716944",
            "pmcid": "PMC5547592",
            "xmlid": "CIT0035"
        },
        {
            "bibentry": "Ahmad, MF, Huff, SE, Pink, J, et al. Identification of non-nucleoside human ribonucleotide reductase modulators. J Med Chem 2015; 58: 9498–509. PMID: 26488902",
            "process_entry": "True",
            "doi": "10.1021/acs.jmedchem.5b00929",
            "pmid": "26488902",
            "pmcid": "PMC4751996",
            "xmlid": "CIT0036"
        },
        {
            "bibentry": "Huff, SE, Mohammed, FA, Yang, M, et al. Structure-guided synthesis and mechanistic studies reveal sweetspots on naphthyl salicyl hydrazone scaffold as non-nucleosidic competitive, reversible inhibitors of human ribonucleotide reductase. J Med Chem 2018; 61: 666–80. PMID: 29253340",
            "process_entry": "True",
            "doi": "10.1021/acs.jmedchem.7b00530",
            "pmid": "29253340",
            "pmcid": "PMC5808567",
            "xmlid": "CIT0037"
        },
        {
            "bibentry": "Fairman, JW, Wijerathna, SR, Ahmad, MF, et al. Structural basis for allosteric regulation of human ribonucleotide reductase by nucleotide-induced oligomerization. Nat Struct Mol Biol 2011; 18: 316–22. PMID: 21336276",
            "process_entry": "True",
            "doi": "10.1038/nsmb.2007",
            "pmid": "21336276",
            "pmcid": "PMC3101628",
            "xmlid": "CIT0038"
        },
        {
            "bibentry": "Labarca, C, Paigen, K. A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 1980; 102: 344–52. PMID: 6158890",
            "process_entry": "True",
            "doi": "10.1016/0003-2697(80)90165-7",
            "pmid": "6158890",
            "xmlid": "CIT0039"
        },
        {
            "bibentry": "Friesner, RA, Banks, JL, Murphy, RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004; 47: 1739–49. PMID: 15027865",
            "process_entry": "True",
            "doi": "10.1021/jm0306430",
            "pmid": "15027865",
            "xmlid": "CIT0040"
        },
        {
            "bibentry": "Halgren, TA, Murphy, RB, Friesner, RA, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004; 47: 1750–9. PMID: 15027866",
            "process_entry": "True",
            "doi": "10.1021/jm030644s",
            "pmid": "15027866",
            "xmlid": "CIT0041"
        },
        {
            "bibentry": "Friesner, RA, Murphy, RB, Repasky, MP, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 2006; 49: 6177–96. PMID: 17034125",
            "process_entry": "True",
            "doi": "10.1021/jm051256o",
            "pmid": "17034125",
            "xmlid": "CIT0042"
        },
        {
            "bibentry": "Jorgensen, WL, Duffy, EM. Prediction of drug solubility from structure. Adv Drug Deliv Rev 2002; 54: 355–66. PMID: 11922952",
            "process_entry": "True",
            "doi": "10.1016/s0169-409x(02)00008-x",
            "pmid": "11922952",
            "xmlid": "CIT0043"
        },
        {
            "bibentry": "Gao, S, Hu, M. Bioavailability challenges associated with development of anti-cancer phenolics. Mini Rev Med Chem 2010; 10: 550–67. PMID: 20370701",
            "process_entry": "True",
            "doi": "10.2174/138955710791384081",
            "pmid": "20370701",
            "pmcid": "PMC2919492",
            "xmlid": "CIT0044"
        },
        {
            "bibentry": "Lepoivre, M, Flaman, JM, Bobe, P, et al. Quenching of the tyrosyl free radical of ribonucleotide reductase by nitric oxide. Relationship to cytostasis induced in tumor cells by cytotoxic macrophages. J Biol Chem 1994; 269: 21891–7. PMID: 7520445",
            "process_entry": "True",
            "pmid": "7520445",
            "xmlid": "CIT0045"
        },
        {
            "bibentry": "Szalai, VA, Brudvig, GW. Reversible binding of nitric oxide to tyrosyl radicals in photosystem II. Nitric oxide quenches formation of the S3 EPR signal species in acetate-inhibited photosystem II. Biochemistry 1996; 35: 15080–7. PMID: 8942675",
            "process_entry": "True",
            "doi": "10.1021/bi961117w",
            "pmid": "8942675",
            "xmlid": "CIT0046"
        },
        {
            "bibentry": "Nyholm, S, Mann, GJ, Johansson, AG, et al. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J Biol Chem 1993; 268: 26200–5. PMID: 8253740",
            "process_entry": "True",
            "pmid": "8253740",
            "xmlid": "CIT0047"
        },
        {
            "bibentry": "Hershko, C. Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Bailliere's Clin Haematol 1994; 7: 965–1000. PMID: 7881162",
            "process_entry": "True",
            "doi": "10.1016/s0950-3536(05)80133-7",
            "pmid": "7881162",
            "xmlid": "CIT0048"
        },
        {
            "bibentry": "Lundberg, JH, Chitambar, CR. Interaction of gallium nitrate with fludarabine and iron chelators: effects on the proliferation of human leukemic HL60 cells. Cancer Res 1990; 50: 6466–70. PMID: 1698536",
            "process_entry": "True",
            "pmid": "1698536",
            "xmlid": "CIT0049"
        },
        {
            "bibentry": "Hakansson, P, Hofer, A, Thelander, L. Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J Biol Chem 2006; 281: 7834–41. PMID: 16436374",
            "process_entry": "True",
            "doi": "10.1074/jbc.m512894200",
            "pmid": "16436374",
            "xmlid": "CIT0050"
        }
    ],
    "localid": "MED-30734609",
    "doi": "10.1080/14756366.2018.1545226",
    "pmid": "10.1080/14756366.2018.1545226",
    "pmcid": "30734609",
    "curator": "BEE EuropeanPubMedCentralProcessor",
    "source_provider": "Europe PubMed Central",
    "source": "https://www.ebi.ac.uk/europepmc/webservices/rest/30734609/fullTextXML",
    "reference_pointers": [
        [
            {
                "n_rp": 0,
                "xref_id": "CIT0001",
                "rp_string": "1–4",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),1,126)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 1,
                "xref_id": "CIT0001",
                "rp_string": "1",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),128,126)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 2,
                "xref_id": "CIT0001",
                "rp_string": "1",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),255,123)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 3,
                "xref_id": "CIT0005",
                "rp_string": "5",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),255,123)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 4,
                "xref_id": "CIT0006",
                "rp_string": "6",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),255,123)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 5,
                "xref_id": "CIT0007",
                "rp_string": "7",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),379,177)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Human ribonucleotide reductase (hRR) is a ubiquitous multi-subunit enzyme that is crucial for cell division and DNA repair1–4. RR catalyses the rate-determining step of dNTP synthesis by removing the 2′ hydroxyl of the ribose to generate a deoxyribose1. RR is critical for the maintenance of a balanced nucleotide pool in cells where imbalances lead to mutator phenotypes1,5,6. RR activity is maintained under tight regulation at the levels of transcription7, allostery1, cellular localisation8, and enzyme inhibition by Sml1 in Saccharomyces cerevisiae9. hRR is a multi-subunit enzyme consisting of a large subunit hRRM1, containing a catalytic site (C-site) and two allosteric sites known as the specificity site (S-site) and the activity site (A-site)1 (Figure 1). hRRM1 associates with the small subunit hRRM2 that houses a free radical essential for catalysis to form the holoenzyme10. ATP and dATP bind the A-site, inducing active and inactive hexamers, respectively11. Binding of dGTP, dTTP, dATP, or ATP to the S-site not only induces dimerisation of hRRM1 but also acts as a selection gate, regulating the relative Kcat/Km for the four NDP substrates: ADP, GDP, CDP, or UDP, respectively1.",
                "pl_xpath": "/article/body/sec[1]/p[1]"
            },
            {
                "n_rp": 6,
                "xref_id": "CIT0001",
                "rp_string": "1",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),379,177)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Human ribonucleotide reductase (hRR) is a ubiquitous multi-subunit enzyme that is crucial for cell division and DNA repair1–4. RR catalyses the rate-determining step of dNTP synthesis by removing the 2′ hydroxyl of the ribose to generate a deoxyribose1. RR is critical for the maintenance of a balanced nucleotide pool in cells where imbalances lead to mutator phenotypes1,5,6. RR activity is maintained under tight regulation at the levels of transcription7, allostery1, cellular localisation8, and enzyme inhibition by Sml1 in Saccharomyces cerevisiae9. hRR is a multi-subunit enzyme consisting of a large subunit hRRM1, containing a catalytic site (C-site) and two allosteric sites known as the specificity site (S-site) and the activity site (A-site)1 (Figure 1). hRRM1 associates with the small subunit hRRM2 that houses a free radical essential for catalysis to form the holoenzyme10. ATP and dATP bind the A-site, inducing active and inactive hexamers, respectively11. Binding of dGTP, dTTP, dATP, or ATP to the S-site not only induces dimerisation of hRRM1 but also acts as a selection gate, regulating the relative Kcat/Km for the four NDP substrates: ADP, GDP, CDP, or UDP, respectively1.",
                "pl_xpath": "/article/body/sec[1]/p[1]"
            },
            {
                "n_rp": 7,
                "xref_id": "CIT0008",
                "rp_string": "8",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[8]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),379,177)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Human ribonucleotide reductase (hRR) is a ubiquitous multi-subunit enzyme that is crucial for cell division and DNA repair1–4. RR catalyses the rate-determining step of dNTP synthesis by removing the 2′ hydroxyl of the ribose to generate a deoxyribose1. RR is critical for the maintenance of a balanced nucleotide pool in cells where imbalances lead to mutator phenotypes1,5,6. RR activity is maintained under tight regulation at the levels of transcription7, allostery1, cellular localisation8, and enzyme inhibition by Sml1 in Saccharomyces cerevisiae9. hRR is a multi-subunit enzyme consisting of a large subunit hRRM1, containing a catalytic site (C-site) and two allosteric sites known as the specificity site (S-site) and the activity site (A-site)1 (Figure 1). hRRM1 associates with the small subunit hRRM2 that houses a free radical essential for catalysis to form the holoenzyme10. ATP and dATP bind the A-site, inducing active and inactive hexamers, respectively11. Binding of dGTP, dTTP, dATP, or ATP to the S-site not only induces dimerisation of hRRM1 but also acts as a selection gate, regulating the relative Kcat/Km for the four NDP substrates: ADP, GDP, CDP, or UDP, respectively1.",
                "pl_xpath": "/article/body/sec[1]/p[1]"
            },
            {
                "n_rp": 8,
                "xref_id": "CIT0009",
                "rp_string": "9",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),379,177)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Human ribonucleotide reductase (hRR) is a ubiquitous multi-subunit enzyme that is crucial for cell division and DNA repair1–4. RR catalyses the rate-determining step of dNTP synthesis by removing the 2′ hydroxyl of the ribose to generate a deoxyribose1. RR is critical for the maintenance of a balanced nucleotide pool in cells where imbalances lead to mutator phenotypes1,5,6. RR activity is maintained under tight regulation at the levels of transcription7, allostery1, cellular localisation8, and enzyme inhibition by Sml1 in Saccharomyces cerevisiae9. hRR is a multi-subunit enzyme consisting of a large subunit hRRM1, containing a catalytic site (C-site) and two allosteric sites known as the specificity site (S-site) and the activity site (A-site)1 (Figure 1). hRRM1 associates with the small subunit hRRM2 that houses a free radical essential for catalysis to form the holoenzyme10. ATP and dATP bind the A-site, inducing active and inactive hexamers, respectively11. Binding of dGTP, dTTP, dATP, or ATP to the S-site not only induces dimerisation of hRRM1 but also acts as a selection gate, regulating the relative Kcat/Km for the four NDP substrates: ADP, GDP, CDP, or UDP, respectively1.",
                "pl_xpath": "/article/body/sec[1]/p[1]"
            }
        ],
        [
            {
                "n_rp": 9,
                "xref_id": "CIT0001",
                "rp_string": "1",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[10]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),557,211)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 10,
                "xref_id": "CIT0010",
                "rp_string": "10",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[12]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),769,122)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 11,
                "xref_id": "CIT0011",
                "rp_string": "11",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[13]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),892,84)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 12,
                "xref_id": "CIT0001",
                "rp_string": "1",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[14]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),977,222)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 13,
                "xref_id": "CIT0012",
                "rp_string": "12–14",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,100)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 14,
                "xref_id": "CIT0015",
                "rp_string": "15",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),102,138)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 15,
                "xref_id": "CIT0016",
                "rp_string": "16",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),102,138)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 16,
                "xref_id": "CIT0017",
                "rp_string": "17–23",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),241,253)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 17,
                "xref_id": "CIT0024",
                "rp_string": "24",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),495,91)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 18,
                "xref_id": "CIT0025",
                "rp_string": "25",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),587,296)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Due to the crucial role hRR plays in replication, it is a major target for cancer chemotherapy12–14. One of the first described hRR inhibitors was hydroxyurea, which targets the di-iron cluster of the hRRM2 subunit to block catalysis15,16. The most common approach for developing inhibitors in the past few decades has involved modifying natural nucleoside substrates, resulting in the production of the clinically used drugs such as gemcitabine, fludarabine, clofarabine, and cladrabine17–23. Gemcitabine is a billion-dollar drug used as a front line treatment of pancreatic cancer24. Gemcitabine derives its main cytotoxicity through DNA chain termination25,26, irreversible inhibition of hRR27,28 and its interactions with several phosphate-binding proteins, such as deoxycytidine deaminase (dCMP deaminase)29, thymidylate synthase30, CTP-synthase31,32, and topoisomerase-133,34. The chain termination activity and lack of specificity exhibited by gemcitabine and other nucleoside-based drugs contribute to the toxic side effects that patients endure17–22. Thus, we have proposed that the development of a selective RR-targeted inhibitor may reduce toxic side effects and expand the therapeutic window35.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 19,
                "xref_id": "CIT0026",
                "rp_string": "26",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),587,296)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Due to the crucial role hRR plays in replication, it is a major target for cancer chemotherapy12–14. One of the first described hRR inhibitors was hydroxyurea, which targets the di-iron cluster of the hRRM2 subunit to block catalysis15,16. The most common approach for developing inhibitors in the past few decades has involved modifying natural nucleoside substrates, resulting in the production of the clinically used drugs such as gemcitabine, fludarabine, clofarabine, and cladrabine17–23. Gemcitabine is a billion-dollar drug used as a front line treatment of pancreatic cancer24. Gemcitabine derives its main cytotoxicity through DNA chain termination25,26, irreversible inhibition of hRR27,28 and its interactions with several phosphate-binding proteins, such as deoxycytidine deaminase (dCMP deaminase)29, thymidylate synthase30, CTP-synthase31,32, and topoisomerase-133,34. The chain termination activity and lack of specificity exhibited by gemcitabine and other nucleoside-based drugs contribute to the toxic side effects that patients endure17–22. Thus, we have proposed that the development of a selective RR-targeted inhibitor may reduce toxic side effects and expand the therapeutic window35.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 20,
                "xref_id": "CIT0027",
                "rp_string": "27",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[8]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),587,296)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Due to the crucial role hRR plays in replication, it is a major target for cancer chemotherapy12–14. One of the first described hRR inhibitors was hydroxyurea, which targets the di-iron cluster of the hRRM2 subunit to block catalysis15,16. The most common approach for developing inhibitors in the past few decades has involved modifying natural nucleoside substrates, resulting in the production of the clinically used drugs such as gemcitabine, fludarabine, clofarabine, and cladrabine17–23. Gemcitabine is a billion-dollar drug used as a front line treatment of pancreatic cancer24. Gemcitabine derives its main cytotoxicity through DNA chain termination25,26, irreversible inhibition of hRR27,28 and its interactions with several phosphate-binding proteins, such as deoxycytidine deaminase (dCMP deaminase)29, thymidylate synthase30, CTP-synthase31,32, and topoisomerase-133,34. The chain termination activity and lack of specificity exhibited by gemcitabine and other nucleoside-based drugs contribute to the toxic side effects that patients endure17–22. Thus, we have proposed that the development of a selective RR-targeted inhibitor may reduce toxic side effects and expand the therapeutic window35.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 21,
                "xref_id": "CIT0028",
                "rp_string": "28",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),587,296)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Due to the crucial role hRR plays in replication, it is a major target for cancer chemotherapy12–14. One of the first described hRR inhibitors was hydroxyurea, which targets the di-iron cluster of the hRRM2 subunit to block catalysis15,16. The most common approach for developing inhibitors in the past few decades has involved modifying natural nucleoside substrates, resulting in the production of the clinically used drugs such as gemcitabine, fludarabine, clofarabine, and cladrabine17–23. Gemcitabine is a billion-dollar drug used as a front line treatment of pancreatic cancer24. Gemcitabine derives its main cytotoxicity through DNA chain termination25,26, irreversible inhibition of hRR27,28 and its interactions with several phosphate-binding proteins, such as deoxycytidine deaminase (dCMP deaminase)29, thymidylate synthase30, CTP-synthase31,32, and topoisomerase-133,34. The chain termination activity and lack of specificity exhibited by gemcitabine and other nucleoside-based drugs contribute to the toxic side effects that patients endure17–22. Thus, we have proposed that the development of a selective RR-targeted inhibitor may reduce toxic side effects and expand the therapeutic window35.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 22,
                "xref_id": "CIT0029",
                "rp_string": "29",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[10]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),587,296)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Due to the crucial role hRR plays in replication, it is a major target for cancer chemotherapy12–14. One of the first described hRR inhibitors was hydroxyurea, which targets the di-iron cluster of the hRRM2 subunit to block catalysis15,16. The most common approach for developing inhibitors in the past few decades has involved modifying natural nucleoside substrates, resulting in the production of the clinically used drugs such as gemcitabine, fludarabine, clofarabine, and cladrabine17–23. Gemcitabine is a billion-dollar drug used as a front line treatment of pancreatic cancer24. Gemcitabine derives its main cytotoxicity through DNA chain termination25,26, irreversible inhibition of hRR27,28 and its interactions with several phosphate-binding proteins, such as deoxycytidine deaminase (dCMP deaminase)29, thymidylate synthase30, CTP-synthase31,32, and topoisomerase-133,34. The chain termination activity and lack of specificity exhibited by gemcitabine and other nucleoside-based drugs contribute to the toxic side effects that patients endure17–22. Thus, we have proposed that the development of a selective RR-targeted inhibitor may reduce toxic side effects and expand the therapeutic window35.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 23,
                "xref_id": "CIT0030",
                "rp_string": "30",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[11]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),587,296)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Due to the crucial role hRR plays in replication, it is a major target for cancer chemotherapy12–14. One of the first described hRR inhibitors was hydroxyurea, which targets the di-iron cluster of the hRRM2 subunit to block catalysis15,16. The most common approach for developing inhibitors in the past few decades has involved modifying natural nucleoside substrates, resulting in the production of the clinically used drugs such as gemcitabine, fludarabine, clofarabine, and cladrabine17–23. Gemcitabine is a billion-dollar drug used as a front line treatment of pancreatic cancer24. Gemcitabine derives its main cytotoxicity through DNA chain termination25,26, irreversible inhibition of hRR27,28 and its interactions with several phosphate-binding proteins, such as deoxycytidine deaminase (dCMP deaminase)29, thymidylate synthase30, CTP-synthase31,32, and topoisomerase-133,34. The chain termination activity and lack of specificity exhibited by gemcitabine and other nucleoside-based drugs contribute to the toxic side effects that patients endure17–22. Thus, we have proposed that the development of a selective RR-targeted inhibitor may reduce toxic side effects and expand the therapeutic window35.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 24,
                "xref_id": "CIT0031",
                "rp_string": "31",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[12]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),587,296)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Due to the crucial role hRR plays in replication, it is a major target for cancer chemotherapy12–14. One of the first described hRR inhibitors was hydroxyurea, which targets the di-iron cluster of the hRRM2 subunit to block catalysis15,16. The most common approach for developing inhibitors in the past few decades has involved modifying natural nucleoside substrates, resulting in the production of the clinically used drugs such as gemcitabine, fludarabine, clofarabine, and cladrabine17–23. Gemcitabine is a billion-dollar drug used as a front line treatment of pancreatic cancer24. Gemcitabine derives its main cytotoxicity through DNA chain termination25,26, irreversible inhibition of hRR27,28 and its interactions with several phosphate-binding proteins, such as deoxycytidine deaminase (dCMP deaminase)29, thymidylate synthase30, CTP-synthase31,32, and topoisomerase-133,34. The chain termination activity and lack of specificity exhibited by gemcitabine and other nucleoside-based drugs contribute to the toxic side effects that patients endure17–22. Thus, we have proposed that the development of a selective RR-targeted inhibitor may reduce toxic side effects and expand the therapeutic window35.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 25,
                "xref_id": "CIT0032",
                "rp_string": "32",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[13]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),587,296)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Due to the crucial role hRR plays in replication, it is a major target for cancer chemotherapy12–14. One of the first described hRR inhibitors was hydroxyurea, which targets the di-iron cluster of the hRRM2 subunit to block catalysis15,16. The most common approach for developing inhibitors in the past few decades has involved modifying natural nucleoside substrates, resulting in the production of the clinically used drugs such as gemcitabine, fludarabine, clofarabine, and cladrabine17–23. Gemcitabine is a billion-dollar drug used as a front line treatment of pancreatic cancer24. Gemcitabine derives its main cytotoxicity through DNA chain termination25,26, irreversible inhibition of hRR27,28 and its interactions with several phosphate-binding proteins, such as deoxycytidine deaminase (dCMP deaminase)29, thymidylate synthase30, CTP-synthase31,32, and topoisomerase-133,34. The chain termination activity and lack of specificity exhibited by gemcitabine and other nucleoside-based drugs contribute to the toxic side effects that patients endure17–22. Thus, we have proposed that the development of a selective RR-targeted inhibitor may reduce toxic side effects and expand the therapeutic window35.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 26,
                "xref_id": "CIT0033",
                "rp_string": "33",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[14]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),587,296)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Due to the crucial role hRR plays in replication, it is a major target for cancer chemotherapy12–14. One of the first described hRR inhibitors was hydroxyurea, which targets the di-iron cluster of the hRRM2 subunit to block catalysis15,16. The most common approach for developing inhibitors in the past few decades has involved modifying natural nucleoside substrates, resulting in the production of the clinically used drugs such as gemcitabine, fludarabine, clofarabine, and cladrabine17–23. Gemcitabine is a billion-dollar drug used as a front line treatment of pancreatic cancer24. Gemcitabine derives its main cytotoxicity through DNA chain termination25,26, irreversible inhibition of hRR27,28 and its interactions with several phosphate-binding proteins, such as deoxycytidine deaminase (dCMP deaminase)29, thymidylate synthase30, CTP-synthase31,32, and topoisomerase-133,34. The chain termination activity and lack of specificity exhibited by gemcitabine and other nucleoside-based drugs contribute to the toxic side effects that patients endure17–22. Thus, we have proposed that the development of a selective RR-targeted inhibitor may reduce toxic side effects and expand the therapeutic window35.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 27,
                "xref_id": "CIT0034",
                "rp_string": "34",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[15]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),587,296)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Due to the crucial role hRR plays in replication, it is a major target for cancer chemotherapy12–14. One of the first described hRR inhibitors was hydroxyurea, which targets the di-iron cluster of the hRRM2 subunit to block catalysis15,16. The most common approach for developing inhibitors in the past few decades has involved modifying natural nucleoside substrates, resulting in the production of the clinically used drugs such as gemcitabine, fludarabine, clofarabine, and cladrabine17–23. Gemcitabine is a billion-dollar drug used as a front line treatment of pancreatic cancer24. Gemcitabine derives its main cytotoxicity through DNA chain termination25,26, irreversible inhibition of hRR27,28 and its interactions with several phosphate-binding proteins, such as deoxycytidine deaminase (dCMP deaminase)29, thymidylate synthase30, CTP-synthase31,32, and topoisomerase-133,34. The chain termination activity and lack of specificity exhibited by gemcitabine and other nucleoside-based drugs contribute to the toxic side effects that patients endure17–22. Thus, we have proposed that the development of a selective RR-targeted inhibitor may reduce toxic side effects and expand the therapeutic window35.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            }
        ],
        [
            {
                "n_rp": 28,
                "xref_id": "CIT0017",
                "rp_string": "17–22",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[16]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),884,176)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 29,
                "xref_id": "CIT0035",
                "rp_string": "35",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[17]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1061,147)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 30,
                "xref_id": "CIT0035",
                "rp_string": "35",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),210,250)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 31,
                "xref_id": "CIT0036",
                "rp_string": "36",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),210,250)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 32,
                "xref_id": "CIT0035",
                "rp_string": "35",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),461,66)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 33,
                "xref_id": "CIT0035",
                "rp_string": "35",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),660,104)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 34,
                "xref_id": "CIT0035",
                "rp_string": "35",
                "rp_xpath": "/article/body/sec[1]/p[4]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[4]),303,193)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 35,
                "xref_id": "CIT0037",
                "rp_string": "37",
                "rp_xpath": "/article/body/sec[1]/p[4]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[4]),639,226)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 36,
                "xref_id": "CIT0013",
                "rp_string": "13",
                "rp_xpath": "/article/body/sec[2]/sec[2]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[2]/p),801,252)",
                "containers_title": [
                    "Materials and methods",
                    "(E)-2-Hydroxy-N'-(2-oxoindolin-3-ylidene)benzohydrazide (TP1)"
                ]
            }
        ],
        [
            {
                "n_rp": 37,
                "xref_id": "CIT0038",
                "rp_string": "38",
                "rp_xpath": "/article/body/sec[2]/sec[16]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[16]/p),1,175)",
                "containers_title": [
                    "Materials and methods",
                    "Protein expression and purification of hRRM1"
                ]
            }
        ],
        [
            {
                "n_rp": 38,
                "xref_id": "CIT0036",
                "rp_string": "36",
                "rp_xpath": "/article/body/sec[2]/sec[17]/p[1]/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[17]/p[1]),1,168)",
                "containers_title": [
                    "Materials and methods",
                    "KD determination by fluorescence quenching"
                ]
            }
        ],
        [
            {
                "n_rp": 39,
                "xref_id": "CIT0039",
                "rp_string": "39",
                "rp_xpath": "/article/body/sec[2]/sec[18]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[18]/p),794,123)",
                "containers_title": [
                    "Materials and methods",
                    "Cancer cell line growth inhibition assay"
                ]
            }
        ],
        [
            {
                "n_rp": 40,
                "xref_id": "CIT0036",
                "rp_string": "36",
                "rp_xpath": "/article/body/sec[2]/sec[19]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[19]/p),1,155)",
                "containers_title": [
                    "Materials and methods",
                    "In silico docking studies"
                ]
            }
        ],
        [
            {
                "n_rp": 41,
                "xref_id": "CIT0040",
                "rp_string": "40–42",
                "rp_xpath": "/article/body/sec[2]/sec[19]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[19]/p),1,155)",
                "containers_title": [
                    "Materials and methods",
                    "In silico docking studies"
                ]
            }
        ],
        [
            {
                "n_rp": 42,
                "xref_id": "CIT0037",
                "rp_string": "37",
                "rp_xpath": "/article/body/sec[2]/sec[19]/p/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[19]/p),157,134)",
                "containers_title": [
                    "Materials and methods",
                    "In silico docking studies"
                ]
            }
        ],
        [
            {
                "n_rp": 43,
                "xref_id": "CIT0040",
                "rp_string": "40–42",
                "rp_xpath": "/article/body/sec[3]/sec[2]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/p),1,118)",
                "containers_title": [
                    "Results",
                    "In silico compound docking interactions with hRRM1"
                ]
            }
        ],
        [
            {
                "n_rp": 44,
                "xref_id": "CIT0035",
                "rp_string": "35",
                "rp_xpath": "/article/body/sec[3]/sec[2]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/p),120,132)",
                "containers_title": [
                    "Results",
                    "In silico compound docking interactions with hRRM1"
                ]
            }
        ],
        [
            {
                "n_rp": 45,
                "xref_id": "CIT0035",
                "rp_string": "35",
                "rp_xpath": "/article/body/sec[3]/sec[2]/p/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/p),253,200)",
                "containers_title": [
                    "Results",
                    "In silico compound docking interactions with hRRM1"
                ]
            }
        ],
        [
            {
                "n_rp": 46,
                "xref_id": "CIT0037",
                "rp_string": "37",
                "rp_xpath": "/article/body/sec[3]/sec[2]/p/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/p),253,200)",
                "containers_title": [
                    "Results",
                    "In silico compound docking interactions with hRRM1"
                ]
            }
        ],
        [
            {
                "n_rp": 47,
                "xref_id": "CIT0035",
                "rp_string": "35",
                "rp_xpath": "/article/body/sec[4]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[4]/p[1]),438,169)",
                "containers_title": [
                    "Discussion and conclusions"
                ]
            }
        ],
        [
            {
                "n_rp": 48,
                "xref_id": "CIT0036",
                "rp_string": "36",
                "rp_xpath": "/article/body/sec[4]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[4]/p[1]),438,169)",
                "containers_title": [
                    "Discussion and conclusions"
                ]
            }
        ],
        [
            {
                "n_rp": 49,
                "xref_id": "CIT0037",
                "rp_string": "37",
                "rp_xpath": "/article/body/sec[4]/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[4]/p[1]),608,212)",
                "containers_title": [
                    "Discussion and conclusions"
                ]
            }
        ],
        [
            {
                "n_rp": 50,
                "xref_id": "CIT0043",
                "rp_string": "43",
                "rp_xpath": "/article/body/sec[4]/p[4]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[4]/p[4]),214,237)",
                "containers_title": [
                    "Discussion and conclusions"
                ]
            }
        ],
        [
            {
                "n_rp": 51,
                "xref_id": "CIT0037",
                "rp_string": "37",
                "rp_xpath": "/article/body/sec[4]/p[5]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[4]/p[5]),865,155)",
                "containers_title": [
                    "Discussion and conclusions"
                ]
            }
        ],
        [
            {
                "n_rp": 52,
                "xref_id": "CIT0044",
                "rp_string": "44",
                "rp_xpath": "/article/body/sec[4]/p[6]/xref",
                "context_xpath": "substring(string(/article/body/sec[4]/p[6]),1,150)",
                "containers_title": [
                    "Discussion and conclusions"
                ]
            }
        ],
        [
            {
                "n_rp": 53,
                "xref_id": "CIT0035",
                "rp_string": "35",
                "rp_xpath": "/article/body/sec[4]/p[7]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[4]/p[7]),202,190)",
                "containers_title": [
                    "Discussion and conclusions"
                ]
            }
        ],
        [
            {
                "n_rp": 54,
                "xref_id": "CIT0037",
                "rp_string": "37",
                "rp_xpath": "/article/body/sec[4]/p[7]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[4]/p[7]),202,190)",
                "containers_title": [
                    "Discussion and conclusions"
                ]
            }
        ],
        [
            {
                "n_rp": 55,
                "xref_id": "CIT0032",
                "rp_string": "32",
                "rp_xpath": "/article/body/sec[4]/p[7]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[4]/p[7]),785,81)",
                "containers_title": [
                    "Discussion and conclusions"
                ]
            }
        ],
        [
            {
                "n_rp": 56,
                "xref_id": "CIT0045",
                "rp_string": "45–49",
                "rp_xpath": "/article/body/sec[4]/p[7]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[4]/p[7]),785,81)",
                "containers_title": [
                    "Discussion and conclusions"
                ]
            }
        ],
        [
            {
                "n_rp": 57,
                "xref_id": "CIT0037",
                "rp_string": "37",
                "rp_xpath": "/article/body/sec[4]/p[7]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[4]/p[7]),867,75)",
                "containers_title": [
                    "Discussion and conclusions"
                ]
            }
        ],
        [
            {
                "n_rp": 58,
                "xref_id": "CIT0035",
                "rp_string": "35",
                "rp_xpath": "/article/body/sec[4]/p[8]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[4]/p[8]),145,253)",
                "containers_title": [
                    "Discussion and conclusions"
                ]
            }
        ],
        [
            {
                "n_rp": 59,
                "xref_id": "CIT0050",
                "rp_string": "50",
                "rp_xpath": "/article/body/sec[4]/p[8]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[4]/p[8]),399,122)",
                "containers_title": [
                    "Discussion and conclusions"
                ]
            }
        ]
    ]
}